The immunoproteasome was successfully targeted with the selective inhibitor ONX-0914, which suppressed the activity of immunoproteasome and synergized with venetoclax against primary CLL cells, and successfully tackled IFNγ-mediated resistance of patient-derived cells to venetoclax. This evidence concerns the gene IFNG and B-cell chronic lymphocytic leukemia.